A0,A0.35_Verb,A1,A2,Polarity,RelatedSentence
2014 - Novartis,announce.01,the signing of,,Affirmative,"Basel , May 19 , 2014 - Novartis announced today the signing of a licensing and commercialization agreement with Ophthotech Corporation ( Ophthotech ) for the exclusive rights to market Fovista速 ( anti-PDGF aptamer ) outside the United States . "
Ophthotech,receive.01,an immediate payment of,,Affirmative,"Under the financial terms of the agreement , Ophthotech will receive an immediate payment of an upfront fee of USD 200 million plus potential future recruitment and other milestone payments . "
Ophthotech,receive.01,royalties,,Affirmative,"In addition , Ophthotech is eligible to receive royalties on ex-US Fovista速 sales . "
patients suffering from,suffer.01,from,,Affirmative,Fovista is being studied in combination with anti-VEGF agents for patients suffering from wet age - related macular degeneration ( wet AMD ) . 
Novartis Pharmaceuticals,develop.02,a co-formulation of Fovista,,Affirmative,Novartis will also develop a co-formulation of Fovista with a Novartis proprietary anti-VEGF treatment . 
Ophthotech,hold.01,the marketing rights to Fovista in,,Affirmative,Ophthotech will hold the marketing rights to Fovista in the United States . 
Novartis Pharmaceuticals,address.02,key unmet needs,,Affirmative,Novartis is committed to addressing key unmet needs in medical retina . 
Fovista in combination with,improve.01,outcomes of patients suffering from,,Affirmative,"Fovista in combination with currently available anti-VEGF treatments could further improve outcomes of patients suffering from avoidable vision loss , said David Epstein , Division Head , Novartis Pharmaceuticals . "
patients suffering from,suffer.01,from,,Affirmative,"Fovista in combination with currently available anti-VEGF treatments could further improve outcomes of patients suffering from avoidable vision loss , said David Epstein , Division Head , Novartis Pharmaceuticals . "
"David Epstein ,",say.01,could further improve outcomes of patients suffering from,,Affirmative,"Fovista in combination with currently available anti-VEGF treatments could further improve outcomes of patients suffering from avoidable vision loss , said David Epstein , Division Head , Novartis Pharmaceuticals . "
wet AMD confirming,confirm.01,our commitment and leadership in,,Affirmative,"If approved , Fovista is expected to be the first to market in this class of therapies for wet AMD confirming our commitment and leadership in the ophthalmology space . "
Fovista,offer.01,a new mechanism of action,,Affirmative,Fovista offers a new mechanism of action to address unmet need to further improve visual acuity and potentially slow disease progression . 
combination therapy of Fovista and Lucentis速,improve.01,baseline visual acuity,,Affirmative,"In Phase II clinical studies , combination therapy of Fovista and Lucentis速 ( ranibizumab ) significantly improved baseline visual acuity in wet AMD patients . "
Novartis Pharmaceuticals,expect.01,to develop Fovista and,,Affirmative,"Novartis expects to develop Fovista and the co-formulation in its proprietary , innovative pre-filled syringe as part of this agreement . "
Novartis Pharmaceuticals,develop.02,Fovista and,,Affirmative,"Novartis expects to develop Fovista and the co-formulation in its proprietary , innovative pre-filled syringe as part of this agreement . "
professionals,help.01,achieve,,Affirmative,"Novartis , through its Alcon and Pharmaceuticals Divisions , is the global leader and partner for physicians in medical retina , and as such , offers the industry ` s most comprehensive portfolio of innovative retina products to support professionals to help achieve the best possible patient outcomes . "
Novartis Pharmaceuticals,hold.01,the marketing rights for Fovista,,Affirmative,Novartis holds the marketing rights for Fovista ( anti-PDGF aptamer ) outside the United States . 
Ophthotech Corporation -LRB- Ophthotech -RRB-,hold.01,the marketing rights to Fovista in,,Affirmative,Ophthotech Corporation holds the marketing rights to Fovista in the United States . 
Lucentis monotherapy,save.01,sight,,Affirmative,Lucentis was designed to save sight and has demonstrated transformational efficacy with individualized dosing in its licensed indications . 
Lucentis monotherapy,demonstrate.01,transformational efficacy,,Affirmative,Lucentis was designed to save sight and has demonstrated transformational efficacy with individualized dosing in its licensed indications . 
Lucentis monotherapy,have.03,an individualized treatment regimen with,,Affirmative,"In most countries , including those in Europe , Lucentis has an individualized treatment regimen with the goal of maximizing visual outcomes while minimizing under - or over-treating patients . "
Lucentis monotherapy,have.03,established safety profile supported by,,Affirmative,Lucentis has a well - established safety profile supported by 43 sponsored clinical studies and real - world experience . 
by,support.01,established safety profile supported by,,Affirmative,Lucentis has a well - established safety profile supported by 43 sponsored clinical studies and real - world experience . 
a clinical development program,enrol.01,"12,500 patients",across indications,Affirmative,"Its safety profile has been well established in a clinical development program that enrolled more than 12,500 patients across indications and there is more than 2.4 million patient - treatment years of exposure since its launch in the United States in 2006 . "
by Genentech and Novartis,develop.02,Lucentis monotherapy,,Affirmative,Lucentis was developed by Genentech and Novartis . 
Genentech Inc.,have.03,the commercial rights to Lucentis in,,Affirmative,Genentech has the commercial rights to Lucentis in the United States . 
Novartis Pharmaceuticals,have.03,exclusive rights in,,Affirmative,Novartis has exclusive rights in the rest of the world . 
The foregoing release,contain.01,looking statements,,Affirmative,"The foregoing release contains forward - looking statements that can be identified by words such as to extend , to receive , if approved , expected , to be , to commercialize , will , committed , could , commitment , offers , potentially , expects , to develop , pipeline , investigational , designed to , goal , or similar terms , or by express or implied discussions regarding potential marketing approvals for Fovista , RTH258 , LFG316 or other investigational treatments in the Novartis medical retina pipeline , potential new indications or labeling for Lucentis or Lucentis pre-filled syringe , and potential future revenues from such products . "
by words,identify.01,looking statements,,Affirmative,"The foregoing release contains forward - looking statements that can be identified by words such as to extend , to receive , if approved , expected , to be , to commercialize , will , committed , could , commitment , offers , potentially , expects , to develop , pipeline , investigational , designed to , goal , or similar terms , or by express or implied discussions regarding potential marketing approvals for Fovista , RTH258 , LFG316 or other investigational treatments in the Novartis medical retina pipeline , potential new indications or labeling for Lucentis or Lucentis pre-filled syringe , and potential future revenues from such products . "
You,place.01,undue reliance on,,Affirmative,You should not place undue reliance on these statements . 
underlying assumptions,prove.01,results may vary materially from those set forth in,,Affirmative,"Should one or more of these risks or uncertainties materialize , or should underlying assumptions prove incorrect , actual results may vary materially from those set forth in the forward - looking statements . "
expectations regarding,regard.01,such products,,Affirmative,"In particular , management ` s expectations regarding such products could be affected by , among other things , the uncertainties inherent in research and development , including unexpected clinical trial results and additional analysis of existing clinical data ; unexpected regulatory actions or delays or government regulation generally ; global trends toward health care cost containment , including ongoing pricing pressures ; general economic and industry conditions ; the company ` s ability to obtain or maintain proprietary intellectual property protection ; unexpected manufacturing issues , and other risks and factors referred to in Novartis AG ` s current Form 20 - F on file with the US Securities and Exchange Commission . "
"by ,",affect.01,expectations regarding,,Affirmative,"In particular , management ` s expectations regarding such products could be affected by , among other things , the uncertainties inherent in research and development , including unexpected clinical trial results and additional analysis of existing clinical data ; unexpected regulatory actions or delays or government regulation generally ; global trends toward health care cost containment , including ongoing pricing pressures ; general economic and industry conditions ; the company ` s ability to obtain or maintain proprietary intellectual property protection ; unexpected manufacturing issues , and other risks and factors referred to in Novartis AG ` s current Form 20 - F on file with the US Securities and Exchange Commission . "
the company `,refer.01,to in,,Affirmative,"In particular , management ` s expectations regarding such products could be affected by , among other things , the uncertainties inherent in research and development , including unexpected clinical trial results and additional analysis of existing clinical data ; unexpected regulatory actions or delays or government regulation generally ; global trends toward health care cost containment , including ongoing pricing pressures ; general economic and industry conditions ; the company ` s ability to obtain or maintain proprietary intellectual property protection ; unexpected manufacturing issues , and other risks and factors referred to in Novartis AG ` s current Form 20 - F on file with the US Securities and Exchange Commission . "
Novartis Pharmaceuticals,provide.01,the information in,,Affirmative,"Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward - looking statements contained in this press release as a result of new information , future events or otherwise . "
Novartis Pharmaceuticals,undertake.01,any obligation,,Affirmative,"Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward - looking statements contained in this press release as a result of new information , future events or otherwise . "
in,contain.01,looking statements contained in,,Affirmative,"Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward - looking statements contained in this press release as a result of new information , future events or otherwise . "
